Professor Ding Yu to Present ATTEC Technology at 2023 Zhongguancun Life Science Park Innovation Summit

Seizing the historic opportunities presented by the new wave of technological revolution and industrial transformation, Zhongguancun Life Science Park, as a key pillar of Beijing’s “Three Cities and One District” master platform for building an international science and technology innovation center, has invested in and attracted numerous biotechnology innovation platforms, thereby fostering agglomeration advantages across the upstream and downstream segments of the industry chain.On March 24, 2023, Zhongguancun Life Science Park Co., Ltd. joined forces with multiple technology platforms to co-host the “2023 Zhongguancun Life Science Park Technology Platform Industry-Research Innovation Summit.”, focusing on core areas such as “AI-enabled new drug discovery,” “breaking through undruggable targets,” “evaluation of biopharmaceuticals,” and “preservation and utilization of clinical biospecimens,” this initiative brings together industry leaders, investment experts, and leading/innovative entrepreneurs to pool diverse strengths and insights. By integrating the entire chain of industry, academia, research, and application, it aims to promote the establishment of a multi-level, broad-spectrum, functional, and open support system for novel innovative technology platforms.

Professor Ding Yu, Fudan UniversityConfirmed attendance at the 2023 Zhongguancun Life Science Park Technology Platform Industry-Research Innovation Summit, and will be present in the afternoon’sAt the 2023 Innovative Drugs and Innovative Technologies Forum—Special Session on Breaking Through Undruggable Targets, a presentation was delivered on《ATTEC: Autophagosome-Tethering Compound for Targeted Lysosomal Degradation》related reports.

Personal Profile

Professor and Doctoral Supervisor at the School of Life Sciences, Fudan University, who has presided over multiple scientific research projects, including key projects funded by the National Natural Science Foundation of China and the National Key R&D Program (as Project Leader). Ding Yu’s research primarily focuses on the molecular mechanisms of autophagy-lysosome targeted degradation (ATTEC technology) and the structure-function relationships of nanobodies. In recent years, he has published more than 30 papers as a corresponding author (including co-corresponding authors) in journals such as Nature (selected as one of the Ten Outstanding Papers of 2019 by Nature), Chemical Society Reviews (cover article), Cell Research (cover article; recipient of the 2021 Sanofi-Cell Research Paper of the Year Award), PNAS, and Molecular Therapy.

How can we leverage clinical sample analysis and proteomics to identify innovative targets with high disease relevance? How can we utilize high-resolution protein crystal structure determination platforms to assess the druggability of these targets? How can we integrate drug design, drug screening, and multidimensional drug evaluation platforms to pave new avenues for the development of therapies against difficult-to-drug targets?

This forum will explore frontier technologies and address the practical needs of the industry, providing insights into the latest technological advancements, druggable targets, new drugs, and molecular mechanisms.

Core Topics

1. ATTEC: Molecular Glue Degraders Targeting the Autophagy-Lysosome Pathway

2. Efficient and Stable TPD Proteomics Analysis Protocol

3. Innovation-Driven New Drug Development

More topics are being confirmed. Stay tuned…

This summit is organized byUnder the guidance of the Administrative Committee of Zhongguancun Life Science Park, Zhongguancun Life Science Park Company, Zhongguancun Life Science Park Incubator Company, and Changfa Zhan CompanyJointSix Core Biotechnology Innovation Platforms: Zhongguancun AI Drug Discovery Platform, Beijing Public Service Platform for Clinical Data and Sample Resources, Cryo-Electron Microscopy Platform, High-Resolution Mass Spectrometry Omics Platform, Biopharmaceutical Evaluation Platform, and Integrated Biological CRO Service Platform, by focusing on core aspects of pharmaceutical R&D such as basic research, target discovery, pilot-scale development, and drug analysis, we can further unlock the industry's potential, better foster the continuous growth of new business models, and promote high-quality development in the field of life sciences and technology.

AsThe Grand Event Co-hosted for the First Time by Zhongguancun Life Science Park and Its Technology Platform, this summit is themed1 Main Forum + 4 Thematic Sub-forumsin a format that further ensures the depth, breadth, cutting-edge nature, and richness of resources. The main forum will serve as a centralized platform for showcasing the insights of industry participants, where numerous leading experts will engage in aOn Multiple Fields of Biotechnology, Including Laboratory Animals and Viral Infections“Brainstorming.” The sub-forum focuses on“High-Quality Development and Sustainable Growth of Biobank Resources,” “AI-Empowered Innovative Drug R&D,” “Breakthroughs in Undruggable Targets,” and “Evaluation of Biologic Drugs”: Four Key DimensionsAn In-Depth Analysis of Innovation and High-Quality Development Pathways and Strategies in Biopharmaceutical Technology.

CollectionOver 40 national academicians, heads of regulatory agencies, leading academics, executives of multinational pharmaceutical companies, directors of Grade A tertiary hospitals, and seasoned investorsincluding keynote speakers, coveringSix Major Circles: Government, Industry, Academia, Research, Healthcare, and Investment, bringing together new ideas, technologies, and business models; focusing on industry hotspots; jointly seeking truth and insight; and engaging in comprehensive, high-level, high-quality, and forward-looking sharing and discussions

Scan the QR code for more conference information and register now.